Clinical Trials on Hepatitis C Virus Genotype 4 Infection

Total 4233 results

Janssen Infectious Diseases BVBA

Completed

Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis

Hepatitis C Virus Infection

United States, Canada
AbbVie

Completed

ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-Administered With Ribavirin (RBV) in Treatment Naïve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis

Chronic Hepatitis C Virus (HCV)
Gilead Sciences

Completed

Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection

Chronic Hepatitis C

New Zealand
AbbVie

Completed

A Study to Evaluate Chronic Hepatitis C Virus (HCV) Infection in Cirrhotic Adults With Genotype 1b (GT1b) Infection (Turquoise-IV)

Chronic Hepatitis C Virus (HCV) Infection
Ain Shams University

Recruiting

Pharmacokinetics of Sofosbuvir/Daclatasvir in HCV-infected Lactating Women

Hepatitis C Virus Infection

Egypt
Foundation for Innovative New Diagnostics, Switzerland
Institute of Tropical Medicine, Belgium

Completed

Evaluation Study of HCV RDTs in Fresh Samples

Hepatitis C Virus Infection

Georgia, Cambodia
Beni-Suef University

Completed

Sofosbuvir/Pegylated-interferon Plus Ribavirin With HCV Genotype 4 (HCV)

Hepatitis C Virus Infection
Janssen R&D Ireland

Completed

A Study in Healthy Participants Investigating the Safety, Tolerability and Plasma Pharmacokinetics (PK) of Single Oral Doses of JNJ-47910382

Hepatitis C Virus Infection

Germany
National Institute on Drug Abuse (NIDA)

Completed

An Hepatitis B Vaccine Model for HIV Vaccine Trials in Drug Users

HIV Infection | Hepatitis B Infection | Hepatitis C Infection

United States
Bristol-Myers Squibb

Completed

Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care in Japanese Patients (Pegylated-interferon Alpha-2a and Ribavirin)

Hepatitis C Infection

Japan
AbbVie

Completed

A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection (TURQUOISE-I)

Hepatitis C Virus Infection | Chronic Hepatitis C | Human Immunodeficiency Virus Infection | Compensated Cirrhosis and Non-cirrhotics
HepNet Study House, German Liverfoundation
Gilead Sciences; Hannover Medical School

Completed

HepNet Acute HCV IV - LDV/SOF FDC in Acute Genotype 1 Hepatitis C Virus Infection

Acute Hepatitis C

Germany
Gilead Sciences

Completed

Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated Cirrhosis

Hepatitis C Virus Infection

Japan
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection (CERTAIN-1)

Hepatitis C Virus | Chronic Hepatitis C Virus
CureTech Ltd
Teva Branded Pharmaceutical Products R&D, Inc.

Terminated

Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I Infection

Chronic Hepatitis C

Israel
Asociacion para el Estudio del Higado
Merck Sharp & Dohme LLC

Unknown

Chronic Hepatitis C in Chronic Hemodialysis Recipients - An Observational Study ((CHINCHERO))

HCV Infection
Kirby Institute

Completed

Direct-acting Antiviral Therapy and Reinfection Among People With Chronic Hepatitis C Virus Infection and Recent Injecting Drug Use in the Prison Setting (SHARP-P)

Hepatitis C, Chronic

Australia
Hospital General de Mexico
AbbVie

Completed

Study to Determine the Hepatitis C Virus Infection Prevalence Among Patients Attended Primarily for Vasculitis

Vasculitis | Chronic Hepatitis c

Mexico
Merck Sharp & Dohme LLC

Completed

Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079)

HCV Infection

United States, Germany, Poland, Sweden
ZymoGenetics
Bristol-Myers Squibb

Unknown

Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection (EMERGE)

Hepatitis C, Chronic

Australia, France, Poland, United States, Spain, Germany, Romania, Canada, Austria, Italy, Puerto Rico
Gilead Sciences

Completed

Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis

Hepatitis C Virus Infection

Japan
Gilead Sciences

Completed

Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor (POLARIS-4)

Hepatitis C Virus Infection

United States, France, United Kingdom, Germany, Canada, Australia, New Zealand, Puerto Rico
Gilead Sciences

Completed

Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis (POLARIS-3)

Hepatitis C Virus Infection

United States, France, United Kingdom, Germany, Australia, Canada, New Zealand, Puerto Rico
Gilead Sciences

Completed

Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection (ASTRAL-2)

Hepatitis C Virus Infection

United States, Puerto Rico
Janssen Infectious Diseases BVBA

Completed

Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis

Hepatitis C Virus Infection

United States, Canada
Kirby Institute
Merck Sharp & Dohme LLC; The University of New South Wales

Completed

Surveillance for Antiviral Resistant Variants in Chronic Hepatitis C Patients (SEARCH-C)

Chronic Hepatitis C Infection

Australia
University of Wuerzburg

Withdrawn

Evaluation of Neurocognitive Performance in Drug Substituted Patients Under Hepatitis C Therapy

Chronic Hepatitis C Infection

Germany
Scynexis, Inc.

Completed

Study of SCY-635, Pegasys and Copegus in Hepatitis C

Hepatitis C Infection

United States, Puerto Rico
Arrowhead Regional Medical Center

Terminated

Treating Hispanic Patients Diagnosed With Hepatitis C Using Boceprevir

Hepatitis C Infection

United States
Gilead Sciences

Completed

Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children With Chronic HCV Infection

Hepatitis C Virus Infection

United States, Belgium, Italy, United Kingdom
Gilead Sciences

Completed

Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV Infection

Hepatitis C Virus Infection

United States, Italy, United Kingdom, Germany, Belgium, Russian Federation, New Zealand, Australia
Gilead Sciences

Completed

Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Participants With Chronic Genotype 3 HCV Infection and Cirrhosis

Hepatitis C Virus Infection

Spain
GlobeImmune

Completed

Safety and Efficacy of the Therapeutic Vaccine GI-5005 Versus Placebo for the Treatment of Chronic Hepatitis C Infection

Hepatitis C

United States
Hepatitis Resource Network
Integrated Therapeutics Group; Subsidiary of Schering-Plough

Completed

PEG-Interferon a-2b + Ribavirin for Treatment of Chronic HRN 005 Hepatitis C Infection in HIV-Infected Persons Not Previously Treated With Interferon

HIV Infections | Chronic Hepatitis C Infection in HIV-Infected Persons

United States
Hepatitis Resource Network
Hoffmann-La Roche

Unknown

HRN 004- Peginterferon a-2a Plus Ribavirin for Chronic Hepatitis C Infection in HIV Infected Persons Who Have Failed to Achieve a Sustained Virologic Response Following Previous Interferon Therapy

HIV Infections | Chronic Hepatitis C Infection in HIV Infected Persons

United States
Bristol-Myers Squibb

Completed

Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribavirin) in Japanese Patients

Hepatitis C Infection

Japan
Imperial College London

Completed

Anticoagulation in Liver Fibrosis in Patients With Hepatitis C Virus Infection

Liver Fibrosis

United Kingdom
Radboud University Medical Center
University Medical Center Groningen; Maastricht University Medical Center; UMC... and other collaborators

Completed

Evaluation of RIBAvirin Plasma COncentrations in Patients With Chronic Hepatitis C Infection Routinely Treated With Modern DAA Regimens (RIBACOP)

Hepatitis C | HCV Coinfection

Netherlands
Beni-Suef University

Completed

Ombitasvir /Paritaprevir/Ritonavir Plus Ribavirin on HCV GT4

Hepatitis C Virus Infection
Asociación Colombiana de Hepatología
Hospital Pablo Tobón Uribe

Not yet recruiting

Adult Screening for Hepatitis c and Linkage to Treatment in Hospitals in Colombia (HCVLINKAGE)

Hepatitis C Virus Infection

Colombia
Liver Institute PLLC

Not yet recruiting

Screening, Treatment, and Eradication of Hep C

Hepatitis C Virus Infection
Haukeland University Hospital
University of Bergen

Unknown

Liver Elastography in Patients Undergoing Treatment for Hepatitis C

Hepatitis C Virus Infection

Norway
VGX Pharmaceuticals, LLC

Completed

Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients

Hepatitis C Virus Infection

United States
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection (ION-2)

Chronic Hepatitis C Virus

United States
Rush University Medical Center
Merck Sharp & Dohme LLC; University of North Carolina, Chapel Hill; Ruth M. Rothstein...

Completed

Study on Immunopathogenesis in HIV and Hepatitis C Coinfection

Fibrosis | HIV Infection | Inflammation | Hepatitis C Infection

United States
Gilead Sciences

Completed

Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection

Hepatitis C Virus Infection

United States, Puerto Rico, New Zealand
Gilead Sciences

Completed

Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection

Hepatitis C Virus Infection

United States, Puerto Rico, New Zealand
Gilead Sciences

Completed

Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis

Hepatitis C Virus Infection

United States, France
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection

Hepatitis C Virus Infection

United States, New Zealand, Australia, United Kingdom
Gilead Sciences

Completed

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen

Hepatitis C Virus Infection

United States

3

Subscribe